High Grade Nootropic CAS 51352-87-5 PRL-8-53 for Memory Enhancement

PRL-8-53 (chemical name Methyl 3-(2-(benzyl(methyl)amino)ethyl)benzoate) is a synthetic nootropic compound discovered in 1972 and patented in 1975 by the late Dr. Nikolaus Hansl, a neuropharmacologist at Creighton University in Omaha, Nebraska.
Preliminary animal tests indicated that the compound was both safe and significantly nootropic, boosting avoidance learning in rodents with no adverse effects. But the real interest in PRL-8-53 was sparked by a 1978 study on human volunteers, which showed that a single dose of the compound could improve word retention scores by more than 200%.
Interest in the compound was further fueled by comments from author and longevity specialist Durk Pearson, who was quoted in ‘High Frontiers’ as follows: “PRL-8-53 is a terrific memory enhancer. Normally you can memorize about seven or eight digits just by looking at them for a second. PRL-8-53 gives the average person a memory span of about 21 to 22 digits.”
The sole human study on PRL-8-53, which was funded by Hansl shortly after he patented the compound, strongly supports the drug’s potential as a nootropic. The study measured word retention in a group of 30 healthy volunteers between 24 and 86 years of age. While participants who had good baseline word retention scores showed little improvements after taking PLR-8-53, participants who had low initial scores or who were over 30 demonstrated major improvement following a 5mg dose of PLR-8-53, in many cases more than doubling their rate of recall.
No adverse effects were noted in the human study.
Anecdotal evidence appears to support claims for PRL-8-53’s safety and nootropic capabilities, but it is still considered an experimental drug because of limited testing.
PRL-8-53 is currently an unscheduled drug and can be legally purchased in the US.

Memory enhancement.

The older subjects in the only human study on PRL-8-53 demonstrated significant improvements in memory after taking a single 5 mg dose. The double-blind study used word memorization as a measure, testing the participants’ ability to recall a list of 12 one-syllable words, first to establish a baseline and then again after ingesting PRL-8-53 or a placebo. The subjects were tested on their ability to recall the words 24 hours after hearing them and then again one week later.
The study results indicate that participants who had higher baseline scores showed the least improvement after ingesting PRL-8-53, while subjects who had demonstrated poorer initial memory or who were over 30 years of age showed significant improvement in recall. In an article on the test, Hansl described the effect on the older participants as follows:
“This group was age 30 or older. As might be expected, rote memory did not come as easily to this group as it did to the younger students. The average retention after 24 hours when on placebo was just under three words out of a possible 12. The average retention after one week was two words. However, the same subjects, when learning subsequent to drug administration, retained an average of 5.85 words after 24 hours and 5.25 words after one week. Again the increases were statistically significant. The improvement expressed in percent of placebo performance was 108% for the 24 hour test and 152% for the one-week recall.”
Many individual nootropic users who have tried PRL-8-53 confirm its memory-boosting effects, in some cases comparing it to a more powerful version of other nootropics such as nefiracetam and Noopept.